Related Experiment Video
Updated: Jul 21, 2026
Mouse Kidney Transplantation: Models of Allograft Rejection
Published on: October 11, 2014
A simulation model to investigate the impact of cardiovascular risk in renal transplantation
1Centre for Mathematics and Computational Science in Medicine, University of Glasgow, Glasgow, Scotland, UK. drm@maths.stir.ac.uk
Insights
Reducing cardiovascular risk factors in patients awaiting kidney transplants offers significant benefits for patient and graft survival. This approach is as effective as improving immunosuppression or increasing transplant numbers.
Area of Science:
- Nephrology
- Cardiology
- Transplantation Medicine
Background:
- Premature cardiovascular disease is the primary cause of mortality and graft loss post-renal transplantation.
- Renal transplant recipients exhibit a high incidence of cardiovascular risk factors impacting survival.
- Cardiovascular risk factors significantly influence both patient and graft survival rates.
Purpose of the Study:
- To develop a discrete event simulation model to assess the impact of reducing cardiovascular risk factors on renal transplant outcomes.
- To evaluate the dynamic interplay between waiting list and transplanted patient populations.
- To investigate the effects of altered transplant policies, including transplant volume, acute rejection rates, and selective transplantation based on cardiovascular risk.
Main Methods:
- Utilized data on cardiovascular risk factors and their correlation with graft and patient survival.
- Developed a discrete event simulation model calibrated to a West of Scotland renal unit population.
- Simulated various policy changes, including transplant numbers, rejection rates, and risk-factor-based transplantation strategies.
Main Results:
- The model predicts that reducing cardiovascular risk in end-stage renal failure patients awaiting transplantation yields benefits comparable to advancements in immunosuppression or increased transplant volumes.
- Addressing cardiovascular risk positively impacts all patients, irrespective of their transplant status.
- Interventions targeting cardiovascular risk factors demonstrate substantial potential for improving transplant outcomes.
Conclusions:
- Reducing cardiovascular risk is a critical strategy to improve outcomes for patients undergoing renal transplantation.
- Proactive management of cardiovascular risk factors offers significant advantages for both transplant recipients and those on the waiting list.
- This approach provides a complementary strategy to enhance graft and patient survival in renal transplantation.
Abstract:
Premature cardiovascular (CV) disease is the leading cause of death following renal transplantation and, as a consequence of death with a functioning graft, it is a major cause of graft loss. Renal transplant recipients have a high prevalence of CV risk factors that influence both patient and graft survival. We used data on the relationship between CV risk factors and graft and patient survivals to develop a discrete event simulation model to study the possible impact of CV risk factor reduction on transplant outcome. The simulation was based on a renal unit in a population that has the risk factor profile of patients from the West of Scotland. We studied the dynamic between patient numbers on the waiting list compared to the transplanted list. After establishing results pertinent to the renal unit, we investigated in what way potential changes to transplant policy affected patient numbers. These perturbations included changing the number of transplants performed, changing the incidence of acute rejection, and interventional policies where patients on the waiting list were selectively transplanted taking into account their CV risk factor profiles. Overall, the model predicts that reducing CV risk in the population with end-stage renal failure awaiting kidney transplantation will have comparable benefits to foreseeable developments in immunosuppression or attainable increases in transplant numbers. Moreover, addressing CV risk has benefits for all patients regardless of whether or not they ultimately receive a kidney transplant.
